NICE Endorses Long-Term Use of AZ’ Brilique

The UK’s National Institute for Health and Care Excellence has approved a final recommendation on a lower dose of AstraZeneca's anti-clotting treatment Brilique for longer-term use in the prevention of heart attack and stroke.

Brilique 90mg is already recommended for 12 months after a heart attack to protect patients from further episodes.

In new guidelines, NICE is now also backing use of the lower 60mg dose for three years beyond this initial treatment period to help prevent another heart attack of stroke in high risk patients.